Sorting out confusion, confliction, and confounding results in clear cell RCC
Which direction should we go in early stage RCC?
The battle for early stage RCC at the European Society of Medical Oncology (ESMO) is turning out to be quite a humdinger this year with quite a few unexpected surprises in store given the variety of trials with different agents and combinations generating a disparate variety of readouts.
Why is this and what can we do/learn from the findings?
In this post, we offer an in-depth discussion and commentary from various GU and IO experts…
To continue reading our latest discussion on oncology new product development plus commentary and analysis BSB subscribers can log-in or you can click to access the content.
This content is restricted to subscribers
